Insider Selling: Immunome (NASDAQ:IMNM) Insider Sells 9,438 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the transaction, the insider directly owned 22,000 shares of the company’s stock, valued at $476,080. The trade was a 30.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Price Performance

Shares of NASDAQ:IMNM remained flat at $21.84 during trading hours on Friday. 1,600,134 shares of the company’s stock traded hands, compared to its average volume of 1,582,220. The firm has a fifty day moving average price of $22.42 and a two-hundred day moving average price of $19.13. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $27.65. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -9.02 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, sell-side analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Trading of Immunome

Several institutional investors have recently modified their holdings of IMNM. Assetmark Inc. acquired a new stake in shares of Immunome in the third quarter valued at $39,000. BNP Paribas Financial Markets grew its holdings in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the period. Strs Ohio bought a new stake in Immunome in the fourth quarter worth about $64,000. Tower Research Capital LLC TRC lifted its holdings in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares during the last quarter. Finally, BIT Capital GmbH acquired a new stake in Immunome in the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Immunome in a research report on Thursday, January 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Guggenheim lifted their price objective on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Leerink Partners set a $40.00 price objective on shares of Immunome in a report on Monday, December 15th. Finally, HC Wainwright started coverage on shares of Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.45.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.